Eisai, Inc.
Global research-driven pharmaceutical company focused on neurology and oncology. Demonstrated capabilities include discovery and development of small molecules and biologics, computational antibody engineering, biomarker assay development for CSF and blood, integration of imaging and fluid biomarkers into trial endpoints, design and conduct of global and adaptive clinical trials, manufacturing and scale-up for oral and parenteral products, liposomal formulation development, and collaborations with academic, industry, and consortium partners to support multi-site trials and diagnostic development.
Industries
N/A
Products
Monoclonal antibody therapeutics targeting amyloid and tau species
Clinical-stage monoclonal antibodies designed to bind and clear pathological amyloid-beta aggregates or tau species, developed with biomarker-driven strategies and target-engagement monitoring.
Small-molecule oncology therapeutics (multi-kinase inhibitors and immune modulators)
Small-molecule kinase inhibitors and immune-modulating agents developed for oncology indications and evaluated in monotherapy and combination regimens, including trials in rare tumor types.
Liposomal cytotoxic formulation for select solid tumors
Liposomal delivery formulation of a microtubule dynamics inhibitor intended to increase intratumoral drug concentration and evaluated in early clinical cohorts.
Monoclonal antibody therapeutics targeting amyloid and tau species
Clinical-stage monoclonal antibodies designed to bind and clear pathological amyloid-beta aggregates or tau species, developed with biomarker-driven strategies and target-engagement monitoring.
Small-molecule oncology therapeutics (multi-kinase inhibitors and immune modulators)
Small-molecule kinase inhibitors and immune-modulating agents developed for oncology indications and evaluated in monotherapy and combination regimens, including trials in rare tumor types.
Liposomal cytotoxic formulation for select solid tumors
Liposomal delivery formulation of a microtubule dynamics inhibitor intended to increase intratumoral drug concentration and evaluated in early clinical cohorts.
Services
Clinical trial sponsorship and management
Design and execution of global multicenter studies, adaptive platform trials, biomarker-driven prevention trials, and consortium-participating studies.
Biomarker assay development and validation
In-house development and analytical validation of CSF and plasma biomarker assays to support target engagement, diagnosis, and trial screening.
Computational molecular simulation for biologics discovery
In silico prediction of antibody–antigen interactions, binding energetics, and rational design of amino-acid substitutions using MD and enhanced sampling methods integrated with experimental workflows.
Liposomal formulation development and clinical evaluation
Formulation of liposome-encapsulated cytotoxics to enhance tumor delivery and retention, with supporting early-phase clinical assessment and combination study design.
Clinical trial sponsorship and management
Design and execution of global multicenter studies, adaptive platform trials, biomarker-driven prevention trials, and consortium-participating studies.
Biomarker assay development and validation
In-house development and analytical validation of CSF and plasma biomarker assays to support target engagement, diagnosis, and trial screening.
Computational molecular simulation for biologics discovery
In silico prediction of antibody–antigen interactions, binding energetics, and rational design of amino-acid substitutions using MD and enhanced sampling methods integrated with experimental workflows.
Liposomal formulation development and clinical evaluation
Formulation of liposome-encapsulated cytotoxics to enhance tumor delivery and retention, with supporting early-phase clinical assessment and combination study design.
Expertise Areas
- Clinical trial management (Phase I–III, prevention and adaptive platform trials)
- Biomarker assay development for CSF and blood-based diagnostics
- Antibody discovery and engineering supported by computational simulation
- Neuroscience and dementia research with imaging and fluid biomarkers
Key Technologies
- Molecular dynamics and enhanced sampling simulations
- High-performance computing for molecular modeling
- Structural biology (X-ray crystallography, cryo-EM)
- Fully automated immunoassay platforms for plasma biomarkers